Milestone Launches Real-World Registry for Approved CARDAMYST Nasal Spray
MIST has more than doubled off its 52-week low of $0.63 on elevated volume (4.8× avg).
Summary
Milestone Pharmaceuticals has announced the initiation of RESET-PSVT, a Phase 4 observational registry designed to collect real-world evidence on its recently FDA-approved CARDAMYST nasal spray for paroxysmal supraventricular tachycardia (PSVT). This study, which will enroll approximately 450 adult patients across 20 sites, aims to characterize usage patterns, patient-reported outcomes, and healthcare utilization. This follows the FDA approval of CARDAMYST in December 2025, as highlighted in the company's recent 10-K, and is a crucial step in supporting its commercialization. The registry is expected to enhance physician confidence and inform future marketing strategies by providing valuable data beyond controlled clinical trials. Investors will be watching for the commencement of enrollment by the end of 2026 and future data readouts to assess the real-world impact and market penetration of the drug.
At the time of this announcement, MIST was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $236.5M. The 52-week trading range was $0.63 to $3.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.